Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV

20 May 2023

Abstract excerpt

Severe fever with thrombocytopenia syndrome virus was first discovered in 2009 as the causative agent of severe fever with thrombocytopenia syndrome. Despite its potential threat to public health, no prophylactic vaccine is yet available. This study developed a heterologous prime-boost strategy comprising priming with recombinant replication-deficient human adenovirus type 5 (rAd5) expressing the surface...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Vector-Borne Animal Diseases
Share to Viral Infections and Outbreaks Research
Share to Viral Infections and Vectors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37210393
DOI: 10.1038/s41598-023-35328-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSVPMID 37210393Read ↗

Heterologous prime-boost regimen elicits potent humoral and cell-mediated immune responses and provides complete protection against SFTSVSemantic proximity Read ↗

Homologous and Heterologous Vaccination Regimens with mRNA and rVSV Platforms Induce Potent Immune Responses Against SFTSV GlycoproteinSemantic proximity Read ↗

Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virusSemantic proximity Read ↗

Safety, Immunogenicity and Efficacy of a Recombinant Vesicular Stomatitis Virus Vectored Vaccine Against Severe Fever with Thrombocytopenia Syndrome Virus and Heartland BandavirusesSemantic proximity Read ↗

Vaccination with single plasmid DNA encoding IL-12 and antigens of severe fever with thrombocytopenia syndrome virus elicits complete protection in IFNAR knockout miceSemantic proximity Read ↗

A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndromeSemantic proximity Read ↗

Development of a novel multi-epitope mRNA vaccine candidate to combat SFTSV pandemicSemantic proximity Read ↗

The Endless Wars: Severe Fever With Thrombocytopenia Syndrome Virus, Host Immune and Genetic FactorsSemantic proximity Read ↗

Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing AntibodiesSemantic proximity Read ↗

Serial Cell-Culture Passage of Severe Fever with Thrombocytopenia Syndrome Virus Attenuates Virulence and Confers Protective Immunity in Mice.Semantic proximity Read ↗

Human monoclonal antibodies that target the SFTSV glycoprotein Gn head from four neutralizing epitope groupsSemantic proximity Read ↗

Mutations that positively affect <i>Bandavirus</i> glycoprotein function on VSV vectored vaccinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.